Neuland Laboratories Ltd.

NSE: NEULANDLAB · Healthcare

₹19,700.00-0.42%06 Nov 2026

Ask the data

Instant answers about Neuland Laboratories Ltd. — computed from its filings, no language model

Market cap₹25,414 cr

Current price₹19,700.00

High / Low₹23,995 / ₹11,555

P/E56.2

P/B12.52

Book value₹1,573.4

ROE22.3%

ROCE26.9%

Debt / equity0.17

Dividend yield0.06%

EPS (TTM)₹350.79

Face value₹10

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 7 periods

	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	763	937	951	1,191	1,559	1,477	2,023
EBITDA	102	147	143	272	463	323	574
Operating margin	13.4%	15.7%	15.0%	22.8%	29.7%	21.9%	28.4%
Interest	22	18	14	13	14	8	24
Depreciation	31	40	49	53	60	66	92
Profit before tax	53	105	82	216	401	346	489
Tax	37	25	18	52	101	86	125
Net profit	16	81	64	164	0	0	364
EPS ₹	12.63	62.85	49.74	127.45	233.89	202.74	283.71
Operating cash flow	—	—	59	237	261	317	347
Capex	—	—	96	66	144	206	396
Dividend paid	—	—	4	6	13	18	15
Total assets	1,231	1,325	—	1,580	1,833	2,180	2,930
Equity	710	786	—	994	1,283	1,525	1,874

Quarterly performance

last 29 quarters · ₹ crore

showing latest 8 of 29 periods

	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	186	204	192	205	241	245	245	201	258	236	256	221	294	269	407	363	418	393	385	440	311	398	328	293	514	440	776	642	450
Operating profit	25	28	30	34	41	47	26	26	43	32	39	29	69	54	120	97	137	121	107	123	62	87	51	34	156	77	307	223	98
Operating margin	13.4%	13.8%	15.7%	16.5%	16.9%	19.0%	10.4%	12.8%	16.6%	13.7%	15.2%	12.9%	23.6%	20.1%	29.4%	26.7%	32.9%	30.9%	27.8%	28.1%	20.0%	21.8%	15.6%	11.8%	30.2%	17.5%	39.6%	34.7%	21.7%
Other income	1	1	2	1	1	0	15	2	0	2	1	1	0	1	8	2	3	2	5	5	4	4	7	8	2	8	12	8	8
Interest	5	6	7	5	4	4	5	4	4	3	3	3	3	3	4	2	4	4	4	3	1	2	2	5	5	7	7	7	7
Depreciation	8	8	8	9	9	10	11	12	12	13	12	13	13	13	13	14	15	15	16	16	16	16	17	20	23	24	25	27	29
Profit before tax	12	16	17	20	29	32	24	12	28	18	24	13	53	39	110	83	122	104	92	130	49	128	39	18	129	54	287	198	69
Tax	4	5	26	5	7	5	7	3	7	5	2	3	15	8	26	21	32	23	25	32	17	26	11	4	33	14	75	50	17
Net profit	0	0	-9	0	0	0	17	9	20	0	22	0	0	0	85	0	0	0	0	0	0	0	0	14	0	41	213	148	52
EPS ₹	6.77	8.66	-7.25	11.82	16.71	20.84	13.48	6.81	15.88	10.08	17.01	7.77	29.97	23.81	65.90	48.23	69.56	63.44	52.66	76.28	25.60	79.18	21.67	10.83	75.49	31.62	165.76	115.10	40.24
Revenue YoY	—	—	—	—	29.6%	20.4%	27.7%	-2.2%	6.8%	-3.6%	4.6%	10.1%	13.9%	13.9%	59.1%	64.1%	42.2%	45.9%	-5.4%	21.1%	-25.6%	1.3%	-14.7%	-33.4%	65.4%	10.5%	136.4%	119.2%	-12.6%
Profit YoY	—	—	—	—	—	—	—	—	—	—	26.0%	-100.0%	-100.0%	—	288.2%	—	—	—	-100.0%	—	—	—	—	—	—	—	—	962.4%	—

Earlier results (standalone, Sep '07 – Jun '19)

₹ crore · from BSE, before the NSE XBRL filings begin

Neuland Laboratories Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 11 periods

	FY09†	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†	FY18†	FY19†
Revenue	310	283	398	451	464	469	465	507	573	519	667
Operating profit	33	30	48	54	65	75	63	77	87	54	—
Operating margin	10.7%	10.7%	12.2%	11.9%	13.9%	15.9%	13.5%	15.1%	15.3%	10.3%	—
Other income	—	—	—	—	—	—	—	5	1	5	3
Interest	14	26	30	33	31	24	27	24	21	20	16
Depreciation	7	13	15	15	15	15	15	16	19	22	26
Profit before tax	14	-11	5	0	15	34	24	41	49	17	—
Tax	3	-4	-0	-2	2	8	9	15	16	3	—
Net profit	12	-7	5	2	14	27	16	26	32	14	16

Quarters

showing latest 8 of 48 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†	MAR '18†	JUN '18†	SEP '18†	DEC '18†	MAR '19†	JUN '19†
Revenue	49	58	64	59	80	84	87	59	69	71	84	90	101	97	110	104	123	110	113	128	118	107	110	122	105	132	110	103	121	108	133	123	127	122	135	150	150	132	141	117	126	116	160	154	169	171	173	181
Operating profit	3	8	7	6	9	9	9	8	10	4	9	6	13	16	14	12	15	13	14	18	16	19	12	23	15	19	18	14	15	13	20	20	18	18	20	25	25	15	22	11	14	10	19	—	15	16	18	19
Operating margin	6.5%	14.1%	10.7%	10.6%	11.3%	11.0%	9.9%	13.4%	14.3%	5.5%	10.3%	6.8%	12.5%	16.1%	12.9%	11.5%	12.1%	12.0%	12.2%	13.9%	13.2%	17.6%	11.2%	18.7%	14.0%	14.7%	16.2%	13.9%	12.7%	12.4%	14.7%	16.3%	14.5%	14.7%	15.0%	16.4%	16.9%	11.5%	15.9%	9.1%	11.4%	8.5%	11.7%	—	8.7%	9.2%	10.7%	10.3%
Other income	1	-0	1	2	—	—	—	—	—	—	—	—	—	—	—	—	—	-4	2	—	—	-1	0	-2	—	-0	0	—	2	1	1	2	1	1	1	0	-0	0	0	3	0	1	0	1	1	0	1	1
Interest	2	3	3	3	3	3	5	5	6	7	8	7	7	8	8	8	9	8	8	8	8	9	6	6	6	6	5	6	6	7	9	7	6	6	5	6	5	5	5	5	5	5	5	4	4	3	5	4
Depreciation	1	1	2	2	2	2	2	3	3	4	3	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4	5	5	5	5	5	6	6	6	6	7	7	8
Profit before tax	1	4	3	1	3	3	7	-4	1	-7	-1	-5	3	4	2	1	-1	-3	4	4	4	5	3	11	5	10	9	5	8	4	9	11	9	9	12	15	15	6	13	3	4	1	9	—	5	6	8	8
Tax	0	-1	0	0	2	1	-1	-1	0	-0	-3	0	0	0	-0	0	0	0	-2	1	1	2	-1	3	1	3	0	2	2	2	3	4	3	3	5	5	5	2	4	1	1	-0	1	—	1	1	1	2
Net profit	1	4	3	1	1	2	8	-3	1	-7	2	-5	3	4	3	1	-1	-3	6	3	3	3	4	8	3	7	9	3	5	2	6	7	6	6	7	10	10	4	9	2	3	1	8	0	4	5	7	6
EPS ₹	2.30	7.50	5.93	1.89	1.61	3.41	14.94	-5.75	1.29	-12.24	4.14	-8.83	5.34	7.32	5.17	1.59	-2.33	-6.30	10.80	4.03	4.04	4.28	5.49	10.22	4.50	8.92	11.22	3.95	6.72	2.21	6.40	8.22	6.98	7.07	7.46	10.93	11.69	4.30	9.58	2.59	2.92	1.36	7.22	0.35	3.43	3.59	5.25	4.38
Revenue YoY	—	—	—	—	62.7%	46.9%	34.9%	1.3%	-14.3%	-16.1%	-3.2%	51.1%	47.1%	36.6%	31.8%	16.0%	22.2%	13.8%	2.3%	23.1%	-4.3%	-2.6%	-2.3%	-4.7%	-11.0%	22.5%	-0.0%	-15.3%	15.4%	-18.1%	20.4%	18.6%	4.8%	13.2%	1.6%	22.1%	17.7%	8.6%	4.4%	-21.6%	-15.9%	-12.5%	13.7%	31.1%	34.1%	47.9%	7.8%	17.6%
Profit YoY	—	—	—	—	-29.8%	-54.6%	151.9%	-403.9%	-19.5%	-459.2%	-72.3%	—	311.4%	—	25.1%	—	-143.8%	-186.1%	109.0%	258.1%	—	—	-28.0%	153.6%	11.3%	108.6%	104.5%	-61.3%	49.7%	-71.8%	-33.8%	141.7%	20.4%	227.1%	16.5%	33.0%	67.6%	-39.3%	28.4%	-76.3%	-75.1%	-68.2%	-5.4%	-82.2%	69.9%	280.2%	-16.4%	1268.3%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 26 periods

	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	-1.3%	-1.3%	-1.3%	2.2%	3.3%	5.9%	5.9%	6.5%	5.4%	2.5%	2.5%	8.5%	8.5%	7.5%	7.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.9%	0.9%	3.4%	14.3%	21.4%	22.3%
ROCE	9.3%	10.8%	12.4%	13.2%	12.2%	12.1%	10.5%	10.3%	10.3%	11.2%	13.1%	20.5%	26.7%	29.9%	35.3%	30.4%	33.9%	26.0%	27.4%	21.4%	14.7%	18.5%	14.6%	24.8%	33.6%	26.9%
Net margin	-1.2%	-1.1%	-1.1%	1.8%	2.8%	4.9%	4.9%	5.3%	4.3%	2.2%	2.1%	7.1%	6.3%	5.8%	5.3%	0.0%	0.0%	0.0%	0.0%	0.0%	1.0%	0.9%	3.5%	13.2%	16.9%	19.6%
EBITDA margin	14.9%	15.8%	17.1%	15.7%	14.9%	14.8%	13.5%	14.7%	14.7%	16.8%	18.4%	22.8%	25.5%	28.0%	30.1%	29.7%	29.9%	27.1%	24.7%	21.9%	17.6%	21.4%	20.2%	28.4%	32.2%	30.6%
Debt / equity	0.35	0.35	0.35	0.18	0.18	0.18	0.18	0.18	0.18	0.23	0.23	0.12	0.12	0.08	0.08	0.06	0.06	0.07	0.07	0.09	0.09	0.10	0.10	0.10	0.10	0.17
Interest coverage	3.86	4.78	5.81	6.88	6.93	6.85	6.38	7.09	7.68	10.00	12.24	17.51	23.98	26.89	29.59	29.69	32.01	34.93	42.76	42.73	23.92	22.63	13.61	21.42	26.41	22.53
Asset turnover	0.64	0.68	0.72	0.71	0.70	0.72	0.71	0.72	0.73	0.71	0.73	0.75	0.84	0.88	0.95	0.85	0.89	0.79	0.79	0.68	0.61	0.61	0.62	0.69	0.81	0.76

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 17 periods

	MAR '14‡	MAR '15‡	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	8	9	9	9	9	13	13	13	13	13	13	13	13	13	13	13	13
Other equity / reserves	116	152	178	537	549	686	697	774	870	981	1,120	1,270	1,382	1,512	1,607	1,862	2,017
Total equity	124	161	187	546	558	699	710	786	883	994	1,133	1,283	1,395	1,525	1,620	1,874	2,030
Borrowings	173	179	169	181	303	210	246	145	200	122	95	83	94	136	160	197	342
Current liabilities	307	295	268	286	367	327	358	369	378	439	403	428	409	466	644	710	619
Non-current liabilities	52	55	69	54	146	104	163	170	164	147	129	122	135	189	270	345	381
Total assets	483	512	524	886	1,071	1,130	1,231	1,325	1,424	1,580	1,665	1,833	1,944	2,180	2,534	2,930	3,030
Property, plant & equipment	130	122	138	155	164	230	338	402	462	457	500	523	531	674	788	892	994
Capital work-in-progress	35	41	40	20	126	104	24	17	29	41	12	46	139	45	140	210	284
Investments	7	7	7	8	8	8	8	7	4	1	0	1	105	109	114	2	2
Inventories	93	113	127	135	175	193	220	248	288	279	296	350	386	386	548	510	552
Receivables	119	129	119	181	194	164	190	218	258	362	325	374	306	316	441	541	294
Cash & equivalents	7	7	10	3	3	8	11	2	6	45	125	88	72	132	41	77	54

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 13 periods

	FY14‡	FY15‡	FY16‡	FY17‡	FY18‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	49	13	45	39	11	70	57	189	59	237	261	317	347
Cash from investing	-10	-14	-20	-42	-116	-77	-49	-84	-94	-62	-150	-298	-424
Cash from financing	-39	1	-24	-0	105	12	-5	-114	38	-136	-69	25	21
Capex	12	15	19	41	134	63	49	105	96	66	144	206	396
Free cash flow	37	-2	26	-2	-122	7	9	84	-37	171	118	111	-49
Dividends paid	1	3	2	1	—	1	5	3	4	6	13	18	15

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹994 cr33%

CWIP

₹284 cr9%

Investments

₹2 cr0%

Inventories

₹552 cr18%

Receivables

₹294 cr10%

Cash & equivalents

₹54 cr2%

Other assets

₹849 cr28%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Neuland Laboratories Ltd.	25,414	19,700.00	56.2	12.52	22.3%

StoxGud checklist: Bullish setup · 7/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-9.0%

6 months+14.0%

1 year+27.9%

3Y CAGR+69.6%

5Y CAGR+64.0%

10Y CAGR+34.4%

50-day avg₹21,389.88

200-day avg₹17,526.22

RSI (14)50

Compare Neuland Laboratories Ltd. with

Acutaas Chemicals vs Neuland Laboratories Krishna Institute of Medical Sciences vs Neuland Laboratories Rubicon Research vs Neuland Laboratories Neuland Laboratories vs Granules India

FAQs

What is the share price of Neuland Laboratories Ltd.?

Neuland Laboratories Ltd. (NEULANDLAB) closed at ₹19,700.00 on NSE on 06 Nov 2026.

What is the market cap of Neuland Laboratories Ltd.?

₹25,414 crore at the latest close.

What is the P/E ratio of Neuland Laboratories Ltd.?

56.2, on trailing-twelve-month earnings from its filings.

How fast is Neuland Laboratories Ltd. growing?

Neuland Laboratories Ltd.: revenue has compounded at 19.3% a year over three years; net profit at 30.6% a year. Latest-quarter revenue is down 12.6% year on year.

How profitable is Neuland Laboratories Ltd.?

On a trailing-twelve-month basis return on equity is 22.3%, return on capital employed 26.9%, operating margin 30.6%, net margin 19.6%.

How much debt does Neuland Laboratories Ltd. have?

Neuland Laboratories Ltd. is lightly geared: debt to equity is 0.17 with borrowings of ₹342 cr against cash of ₹54 cr (balance sheet of 2026-09-30). Operating profit covers interest 22.5 times.

Financials parsed from Neuland Laboratories Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from SEP '19, annual from FY20, balance sheet from Mar '14. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.